Daniel A. Vallera

9.7k citations

203 papers · 8.0k indexed · h-index 52

Impact in

Immunology top 0.2%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Toxin Mechanisms and Immunotoxins
- Immunotherapy and Immune Responses
Hematology top 0.2%
- Hematopoietic Stem Cell Transplantation

Papers in

Immunology 156
- Toxin Mechanisms and Immunotoxins 78
- Immune Cell Function and Interaction 46
- Immunotherapy and Immune Responses 39
- T-cell and B-cell Immunology 31
Biotechnology 43
- Transgenic Plants and Applications 34

Co-authors: Bruce R. Blazar Angela Panoskaltsis‐Mortari Jeffrey S. Miller Patricia A. Taylor Martin Felices John H. Kersey CHRISTINE C. B. SODERLING D.A. Todhunter
Journals: The Journal of Immunology (24 papers)Blood (19 papers)Transplantation (18 papers)Journal of Neuro-Oncology (9 papers)Clinical Cancer Research (8 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Daniel A. Vallera

200 papers receiving 7.9k citations

Peers

Countries citing papers authored by Daniel A. Vallera

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Vallera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Vallera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Vallera more than expected).

Fields of papers citing papers by Daniel A. Vallera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Vallera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Vallera. The network helps show where Daniel A. Vallera may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel A. Vallera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel A. Vallera Line = papers co-authored together Daniel A. Vallera links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA SHILAP Revista de lepidopterología ·Alan Curley, Martin Felices, Behiye Kodal, Jeffrey S. Miller, Daniel A. Vallera	2023	2
2	Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings Molecular Cancer Therapeutics ·Naiyang Xue, Daniel A. Vallera, Carston R. Wagner	2022	4
3	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation Blood Advances ·Zachary Davis, Martin Felices, Todd Lenvik, Sujan Badal, Charles Tatlock, Peter Hinderlie, James L. Riley, Daniel A. Vallera, Bruce R. Blazar, Jeffrey S. Miller	2021	26
4	GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts Blood ·Erica D. Warlick, Daniel J. Weisdorf, Daniel A. Vallera, Sven Nolte, Dixie Lewis, Nessren Mohamed Baha El Deen Mohamed, E Benito, Martin Felices, Jeffrey S. Miller	2020	29
5	Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager Cancer Immunology Research ·Martin Felices, Todd Lenvik, Behiye Kodal, Alexander J. Lenvik, Peter Hinderlie, Laura E. Bendzick, Dawn K. Schirm, Michał F. Kamiński, Ron McElmurry, Melissa A. Geller, Craig E. Eckfeldt, Daniel A. Vallera, Jeffrey S. Miller	2020	51
6	Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization Journal of Clinical Medicine ·Cathrine Elisabeth Olsen, Lawrence H. Cheung, Anette Weyergang, Kristian Berg, Daniel A. Vallera, Michael G. Rosenblum, Pål Kristian Selbo	2019	15
7	Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR Molecular Cancer Therapeutics ·Antonella Borgatti, Joseph S. Koopmeiners, Aaron L. Sarver, Daouda SÈNE, S L Ledbetter, D.A. Todhunter, Anthony E. Rizzardi, Jonathan C. Henriksen, Stephen C. Schmechel, Colleen L. Forster, Jong Hyuk Kim, Jerry Froelich, Baskin Chaim, Michael S. Henson, Matthew Breen, Kerstin Lindblad‐Toh, Alan Curley, Mei Berkat Syukur Gea, Jaime F. Modiano, Daniel A. Vallera	2017	33
8	Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models Blood ·Martin Felices, Craig E. Eckfeldt, Todd Lenvik, Behiye Kodal, Alexander J. Lenvik, Laura E. Bendzick, Caitlin Ryan, Melissa A. Geller, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller	2017	1
9	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function Clinical Cancer Research ·Daniel A. Vallera, Martin Felices, Ron McElmurry, Valarie McCullar, Xianzheng Zhou, Joerg Uwe Schmohl, Bin Zhang, Alexander J. Lenvik, Angela Panoskaltsis‐Mortari, Michael R. Verneris, Jakub Tolar, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller	2016	295
10	Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells Cancer Biotherapy and Radiopharmaceuticals ·Daniel A. Vallera, Bin Zhang, Michelle Gleason, Seunguk Oh, Louis M. Weiner, Dan S. Kaufman, Valarie McCullar, Jeffrey S. Miller, Michael R. Verneris	2013	82
11	Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors International Journal of Cancer ·三浦登, Aric M. Frantz, 蔺祥星, Erin B. Dickerson, Daniel A. Vallera, Jaime F. Modiano	2013	30
12	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia Blood ·Qing Zhou, Meghan E. Munger, Steven L. Highfill, Jakub Tolar, Brenda J. Weigel, Megan Riddle, Arlene H. Sharpe, Daniel A. Vallera, Miyuki Azuma, Bruce L. Levine, Carl H. June, William J. Murphy, David H. Munn, Bruce R. Blazar	2010	230
13	Radiotherapy of CD45-Expressing Daudi Tumors in Nude Mice with Yttrium-90-Labeled, PEGylated Anti-CD45 Antibody Cancer Biotherapy and Radiopharmaceuticals ·Daniel A. Vallera, Monica P. Bonitatis, Elizabeth Taras, Martin W. Brechbiel, M. Fendler, Angela Panoskaltsis‐Mortari, Linda J. Burns	2007	6
14	Radiotherapy of CD19 Expressing Daudi Tumors in Nude Mice with Yttrium-90-Labeled Anti-CD19 Antibody Cancer Biotherapy and Radiopharmaceuticals ·Daniel A. Vallera, Michael K. Elson, Martin W. Brechbiel, Kathryn E. Dusenbery, Linda J. Burns, W Jaszcz, Norma K.C. Ramsay, V. N. Sales Neto, Théo Kziazyk, John E. Wagner, Ellen S. Vitetta, John H. Kersey	2004	14
15	Immunotoxin therapy for CNS tumor Journal of Neuro-Oncology ·Edward Rustamzadeh, Walter C. Low, Daniel A. Vallera, Walter A. Hall	2003	28
16	LACK OF GVHD ACROSS CLASSICAL SINGLE MINOR HISTOCOMPATIBILITY (miH) LOCUS BARRIERS IN MICE1,2 Transplantation ·Bruce R. Blazar, Derry C. Roopenian, Patricia A. Taylor, Gregory J. Christianson, Angela Panoskaltsis‐Mortari, Daniel A. Vallera	1996	20
17	Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. PubMed ·Burkhard Jansen, Daniel A. Vallera, W Jaszcz, Dat Nguyen, John H. Kersey	1992	44
18	Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. The Journal of Immunology ·Fatih M. Uckun, Damian E. Myers, J A Ledbetter, Legkonogov Eg, K Gajl-Peczalska, Daniel A. Vallera	1988	37
19	Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. The Journal of Immunology ·Fatih M. Uckun, Amalia Hidayanti, Richard J. Youle, Daniel A. Vallera	1985	61
20	Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. The Journal of Experimental Medicine ·Daniel A. Vallera, 克彦土井, David M. Neville, JH Kersey	1982	51

About Daniel A. Vallera

Daniel A. Vallera is a scholar working on Immunology, Biotechnology, Hematology, Structural Biology and Oncology, having authored 203 papers that have together received 8.0k indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (78 papers), CAR-T cell therapy research (52 papers), Monoclonal and Polyclonal Antibodies Research (49 papers), Immune Cell Function and Interaction (46 papers), Hematopoietic Stem Cell Transplantation (41 papers), Immunotherapy and Immune Responses (39 papers), Transgenic Plants and Applications (34 papers) and T-cell and B-cell Immunology (31 papers). The work is most often cited by research in Immunology (5.3k citations), Hematology (2.3k citations), Oncology (3.1k citations), Biotechnology (965 citations) and Radiology, Nuclear Medicine and Imaging (1.2k citations). Daniel A. Vallera has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Bruce R. Blazar, Angela Panoskaltsis‐Mortari, Jeffrey S. Miller, Patricia A. Taylor, Martin Felices, John H. Kersey, CHRISTINE C. B. SODERLING, D.A. Todhunter, Fatih M. Uckun and Michael R. Verneris. Their work appears in journals such as The Journal of Immunology, Blood, Transplantation, Journal of Neuro-Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact